101366Novel Teriparatide (PTH) FormulationClosedCollaborative R&DInnovate UKOsteoporosis is a debilitating disease. About 55% of people over 50 are at risk of developing osteoporosis, with post-menopausal women at greatest risk. Osteoporosis affects 2 million people in the UK and 70,000 suffer hip fractures (among the worst in the EU). Treatment of hip fracture alone costs the NHS £2bn annually. Teriparatide (PTH) is currently the most effective medical intervention. Daily PTH injection has resulted in a 66-90% decrease in vertebral fractures and about a 50% drop in non-vertebral fractures. However, the current PTH product must be stored under refrigerated conditions. Whilst most bone physicians believe that PTH is a good drug, few actually prescribe it as its use is very restrictive in terms of travel and work, over a long treatment time (24 months) as well as the high cost. The aim of this project is to develop a generic version of PTH that is cost effective and can be used by patients "on the go" by use of the patented, needle free, Glide SDI® technology.